NCT05638880 is a Phase 2 clinical trial of Valsartan 80 mg in Diabetic Nephropathies, sponsored by Mostafa Bahaa.

Who is sponsoring NCT05638880?

NCT05638880 is sponsored by Mostafa Bahaa.

What drugs are being tested in NCT05638880?

Interventions in NCT05638880: Valsartan 80 mg, Empagliflozin 10 MG, Levocetirizine.

What condition does NCT05638880 study?

NCT05638880 studies Diabetic Nephropathies.

Is NCT05638880 still recruiting?

NCT05638880 is currently completed. Last updated 31 March 2026.

Last reviewed 2026-03-31 · How we verify

NCT05638880

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Clinical Study to Evaluate the Possible Efficacy and Safety of Levocetirizine in Patients With Diabetic Kidney Disease

Completed Phase 2 Last updated 31 March 2026

What this trial tests

Phase 2 trial testing Valsartan 80 mg in Diabetic Nephropathies in 60 participants. Completed in 20 December 2025.

Timeline

20 December 2022

Primary endpoint
20 December 2025

20 December 2025

Quick facts

Lead sponsor	Mostafa Bahaa
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	60
Start date	20 December 2022
Primary completion	20 December 2025
Estimated completion	20 December 2025
Sites	1 location across Egypt

Drugs / interventions tested

Valsartan 80 mg — full drug profile →
Empagliflozin 10 MG — full drug profile →
Levocetirizine (LEVOCETIRIZINE) — full drug profile →

Conditions studied

Diabetic Nephropathies — all drugs for Diabetic Nephropathies →

Sponsor

Mostafa Bahaa — full company profile →

Who can join

Adults 40 to 65, any sex, with Diabetic Nephropathies. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The prevalence of diabetes mellitus is increasing worldwide, and its complications are one of the leading causes of mortality from non-communicable diseases. Due to the high prevalence of diabetes and because 30-40% of diabetic patients \[both type 1 (T1DM) and type 2 (T2DM) diabetes mellitus\] develop kidney dysfunction, diabetic nephropathy (DN) is the main cause of end-stage renal disease worldwide. The renin-angiotensin-aldosterone system (RAAS), endothelin, and urotensin II are vasoactive hormones that have been extensively studied as other mediators although their relation to diabetic nephropathy is still speculative.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Efficacy of levocetirizine in reducing albuminuria and inflammatory biomarkers in patients with diabetic kidney disease: A randomized controlled trial.
Rizk MA, El-Haggar SM, Ibrahim OM, Ghazi HA. · · 2025 · PMID 40946347 · DOI 10.1016/j.jdiacomp.2025.109175

Verify or expand the search:

Other trials of Valsartan 80 mg

Trials testing the same drug.

NCT05269615 — Exercise-induced Erythropoiesis: the Mechanistic of Angiotensin II · Phase 4 · unknown
NCT05881720 — Sacubitril/Valsartan Versus Valsartan in Heart Failure · Phase 4 · completed
NCT03432468 — Effect of Fully Blocking Type 1 Angiotensin Receptor on Target Organ Damage of Postmenopausal Hypertensive Women · NA · unknown
NCT03180593 — Efficacy and Safety of Valsartan and Nebivolol/Valsartan in Hypertensive Patients With LVH · Phase 4 · completed

Other recruiting trials for Diabetic Nephropathies

Currently open trials in the same condition.

NCT07444203 — Transformative Research in Diabetic Nephropathy 2.0 · recruiting
NCT07187713 — ACE Reno, Pico Cell Matrix and Its Effect on eGFR in Chronic Kidney Diseases · Phase 4 · recruiting
NCT06778018 — Nutritional Outcomes of Lotus Seed (Nelumbo Nucifera) on Diabetic Sensorimotor Polyneuropathy · NA · recruiting
NCT06441591 — Clinical Outcome of Vinpocetine in Diabetic Nephropathy · Phase 2, PHASE3 · recruiting
NCT06431477 — Efficacy and Safety of Telmisartan Compared With Losartan · Phase 4 · recruiting

Other Mostafa Bahaa trials

Trials by the same sponsor.

NCT06995339 — Comparative Clinical and Biochemical Study Evaluating the Effectiveness of Metformin Versus Febuxostat on Gouty Obese No · Phase 2 · recruiting
NCT06924658 — Metformin in Safety and Efficacy in Gouty Patients · Phase 2 · recruiting
NCT06875518 — Comparative Study of Blood Loss in Total Laparoscopic Hysterectomy by Ligation the Uterine Arteries in Different Techniq · NA · recruiting
NCT06762314 — Efficacy and Safety of Empagliflozin or Semaglutide in Overweight/Obese Patients With Type 1 Diabetes · Phase 2 · recruiting
NCT06329882 — Doxycycline in Type II Diabetes · Phase 1, PHASE2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05638880 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Mostafa Bahaa
Last refreshed: 31 March 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05638880.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing